Catherine Shaffer

Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.

The firm recently started treating patients in a Phase I trial of its pol theta helicase inhibitor and filed an IND for its Werner helicase-targeted drug candidate.

The firm expects to begin Phase I trials of mesothelin-targeted ZW171 and FRα-targeted ZW191 in the coming months in difficult-to-treat cancers.

The firm has enough funds to complete ongoing trials, but needs more for a Phase III trial of palazestrant with Novartis' Kisqali and its KAT6 inhibitor program.

The firm is working with providers to expand the use of Yescarta and Tecartus as competition from other CAR T-cell therapies and bispecifics heats up.

The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.

The firm is building a case for clinical utility of its gene expression test for cancer of unknown primary following a successful validation study.

Despite a disappointing Phase III failure in triple-negative breast cancer, Truqap sales were strong in patients with biomarker-altered hormone-sensitive disease.

The firm is looking for funding and partnerships to continue demonstrating the capabilities of its mechanistic approach that simulates treatment responses in in silico tumor models.

Based on the performance of the ENLIGHT-DP platform in a recently published study, the firm is planning to generate registrational data.